Extracellular Vesicles with PD-L1 Targeting Peptides for Senescent Cell Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Senescent cells accumulate with age and contribute to aging-related pathologies and diseases, necessitating effective methods to target and manage these cells.
Innovation Solution
Development of extracellular vesicles equipped with a targeting peptide, such as a PD-L1 binding peptide, and an active agent, including long non-coding RNAs like MIR503HG, to specifically target and deliver therapeutic agents to senescent cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional methods are used to treat senescent cells, then treatment specificity is insufficient, but this leads to off-target effects and limited therapeutic efficacy
Solution Approach 1:
The patent applies local quality by designing extracellular vesicles with specific surface properties (PD-L1 targeting peptides) that enable selective interaction with senescent cells. The vesicles are engineered to have distinct characteristics that allow them to home in on and deliver payloads specifically to senescent cells, while avoiding normal cells. This resolves the contradiction by achieving high treatment specificity without causing off-target effects.
Solution Approach 2:
The patent uses extracellular vesicles as intermediary carriers between the therapeutic payload and senescent cells. These vesicles serve as mediators that can be functionalized with targeting peptides to recognize senescent cells, transport the payload, and facilitate controlled delivery. This intermediary approach enables precise targeting while maintaining safety, resolving the specificity-versus-off-target contradiction.
2Productivity
If non-specific delivery methods are used, then delivery simplicity is maintained, but therapeutic efficacy is reduced due to lack of targeting
Solution Approach 1:
The patent creates a universal platform using extracellular vesicles that can be adapted for different therapies. The same vesicle platform can carry various payloads (drugs, RNAs, proteins) and target different senescent cell populations by simply changing the surface peptide conjugates. This multi-functionality achieves high therapeutic efficacy across different applications without proportionally increasing complexity, as the core delivery mechanism remains the same.
Solution Approach 2:
The patent performs preliminary action by pre-functionalizing extracellular vesicles with targeting peptides and other surface modifications before administration. This preparation step ensures that the vesicles are already equipped for specific targeting and payload delivery upon administration, eliminating the need for complex in-situ activation or modification. This preliminary preparation achieves high efficacy while keeping the overall system manageable in complexity.
3Reliability
If senescent cells are left untreated, then treatment simplicity is maintained, but aging-related pathologies progress
Solution Approach 1:
The patent applies self-service by designing extracellular vesicles that autonomously recognize and bind to senescent cells through PD-L1 targeting peptides without requiring external guidance or complex control systems. The vesicles self-navigate to the target, self-assemble the delivery complex, and self-release the payload. This autonomous operation ensures reliable therapeutic effect while simplifying the treatment implementation, as no complex administration protocols are needed beyond standard IV or local injection.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The described approach enables targeted delivery of therapeutic agents into senescent cells, potentially reversing cellular senescence and mitigating age-related diseases, as demonstrated by improved vascular health and reduced senescence markers in treated subjects.
Implementation Method 1
the targeting peptide can be a programmed death-ligand 1 (PD-L1) binding peptide having at least 80% sequence identity to SEQ ID NO: 1
Data Source
AI summary
Described herein are extracellular vesicles and methods of using the extracellular vesicles. The extracellular vesicles can include a targeting peptide and an active agent, where the targeting peptide targets senescent cells.